Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.Nacuity Pharmaceuticals, Inc.
  • About Us
  • Our Science
  • Pipeline
  • Development Programs
  • Investors & Collaborators
  • News
  • Medical Information
    • Publications
    • Expanded Access
  • Contact
  • Privacy Policy
  • Disclaimer
✕

Investors & Collaborators

Investors | Academic Research | Industrial Collaborators

Investors

Retinal Degeneration Fund logo

Tarnagulla Ventures

Academic Research

Johns Hopkins Medicine

University
UNT Health Science Center

Howard Hughes Medical Institute

Wilmer Eye Institute
North Texas Eye Research Institute
Robert Gordon University Aberdeen

University of Pennsylvania

The Florey Institute of Neuroscience & Mental Health

Baylor College of Medicine
The University of Adelaide Ophthalmic Research Laboratory
Ophthalmic Research Laboratory
Doheny Eye Institute
(provider of Imaging Analysis)

Industrial Collaborators

Statistics Data Corporation
Nanoform logo

integral biosystems logo

MedPharm
Eurofins Discovery
Heidelberg Engineering

CMAX Clinical Trials and Research

PCI Pharma Services

Acclime

Arctic Therapeutics

© 2017 - 2025 Nacuity Pharmaceuticals, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
✕
conner_200

Halden Conner

Chairman, CEO, Co-Founder


  • Former Alcon Laboratories Board Member
  • Former Wilmer Advisory Council Member
  • Co-founder, Protom International
✕
mwall_2

G. Michael Wall, Ph.D.

SVP, CSO


  • 22 years at Alcon Laboratories, directing all phases of ophthalmic, otic, nasal drug development, numerous products
  • 56 patents, 120 publications & abstracts, 2 books, 9 book supplements, 3 chapters
  • Directed more than 40 clinical trials
  • PhD, Medicinal Chemistry, University of Mississippi School of Pharmacy
  • Harvard Business School AMP
✕
kern

Jami R. Kern, MBA, Ph.D.

SVP, CCO


  • Extensive experience, pharmaceutical and medical device industries
  • Led clinical development and medical affairs at Alcon Research for 15 years
  • MBA, Neeley School of Business at TCU, Ph.D. in Biomedical Science, Molecular Biology & Biochemistry, UNT Health Science Center
✕
anderson_200

Lee Anderson, M.D.

Ophthalmologist in Residence


  • Over 20 years in practice specializing in Ophthalmology and Retinal Disease
  • M.D., University of Texas Medical Branch
  • Fellowship Bascom Palmer Eye Institute
✕
lieser_200

Charles Lieser, J.D., CPA

CFO


  • Owner, Weaver, LLP, 32 years
  • 40 plus years experience public accounting
  • Principal and advisor to numerous companies
✕
cagle_200

Gerald D. Cagle, Ph.D.


  • Former Global Head R&D, Chief Scientific Officer, & VP Regulatory Affairs, Alcon Laboratories
  • >20 issued patents and numerous peer reviewed scientific articles
  • Director, Aerie, Clearside Biomedical, GrayBug Drug Delivery and FFB-CRI
✕
Emmett-Cunningham-Headshot200x200

Emmett T. Cunningham, Jr.
M.D., Ph.D., MPH


  • Senior Partner, HealthQuest Capital Management
  • Co-Founder and Executive Chairman, Eyconis, Inc.
  • Former Senior Managing Director, Blackstone, Inc.
  • Co-Founder and former Chairman, Ophthalmology Innovation Summit (OIS)
✕
russell_kelley-05_crop_bod

Russell Kelley, Ph.D., M.B.A.


  • Managing Director, RD Fund
  • Former Scientist, Director and Head of preclinical, Tengion
  • Board Director, Opus Genetics and SparingVision
  • Board Observer, Atsena Therapeutics, Perceive Bio, Amber Bio and Perceive Pharma
✕
steele_200

Robin Steele, J.D., LLM


  • Director, Daré Bioscience, Inc., Coagulant Therapeutics, Inc. and Alveo Technologies, Inc.
  • Former Senior Vice President, General Counsel, and Secretary of InterMune, Inc.
  • Former Vice President of Legal Affairs for North America, Elan Pharmaceuticals, Inc.
✕
wohlberg_200

David Wohlberg, Esq.


  • Vice-Chairman, Co-Founder, Nacuity Pharmaceuticals, Inc.
  • Former President, ImmunoCellular Therapeutics, Inc.
  • Of Counsel, TroyGould PC
✕
yerxa_200

Benjamin R. Yerxa, Ph.D.


  • President, Opus Genetics
  • Former CEO, FFB and RD Fund
  • Former President and Chief Scientific Officer, Envisia Therapeutics
  • Former Chief Scientific Officer, Liquidia Technologies
  • Former Vice President for Research and Development, Clearside Biomedical
✕
birch_200

David Birch, Ph.D.


  • Scientific Director, Retina Foundation of the Southwest
  • Director, Rose-Silverthorne Retinal Degenerations Laboratory
  • Ph.D., University of California, Santa Barbara
✕
holekamp

Nancy Holekamp, M.D.


  • Professor of Clinical Ophthalmology and Visual Sciences, Washington University School of Medicine
  • Director of Retina Services, Pepose Vision Institute
  • M.D., Johns Hopkins University School of Medicine
✕
Richard Lindstrom picture

Richard L. Lindstrom, M.D.


  • Founder and Attending surgeon, Minnesota Eye Consultants
  • Senior Lecturer and Trustee, University Foundation at the University of Minnesota
  • Executive Committee and Board of Directors, American Society of Cataract and Refractive Surgery
  • M.D., University of Minnesota
✕
pennesi_200

Mark Pennesi, M.D., Ph.D.


  • Professor and Chief of Ophthalmic Genetics, Casey Eye Institute
  • Prevent Blindness and FFB development awards for transitional research in RP
  • M.D./Ph.D., Baylor College of Medicine
✕
stout_200

Tim Stout, M.D., Ph.D., MBA


  • Director, Cullen Eye Institute, Baylor College of Medicine
  • Chair, Department of Ophthalmology, Baylor College of Medicine
  • M.D./Ph.D., Baylor College of Medicine
  • MBA University of Oregon
✕
dorfman_200

Scott Dorfman


  • Co-Founder, CEO and Chairman, Odylia Therapeutics
  • Founder, former Chairman and CEO of Innotrac Corporation
  • Board Member: Dropoff, DriverReach, Complemar, Fulcrum Equity Partners, BioNeex, Usher 2020 Foundation
  • BBA, University of Georgia
✕
feller_200

Daniel Feller


  • Owner and CEO, Talisman Healthcare
  • COO, GEM42S Ltd.
  • Board Member: Genetic Cures Australia
  • B.A. (Hons.) in French with International Relations, University of Warwick